CRISPR-Cas CLINICAL TRIALS

All | TALEN | ZFN | MegaNuclease | megaTAL | CAS-CLOVER | Base Editor

Bacterial Infection

E. coli infections (NCT05277350)
Sponsors:
SNIPR Biome

IND Enabling

Phase I

Phase II

Phase III

Urinary Tract Infections, UTI, (NCT04191148)

Open access

Sponsors:
Locus Biosciences

IND Enabling

Phase I

Phase II

Phase III

Blood

Beta-Thalassemia, BT, (NCT03728322)
Sponsors:
Allife Medical Science and Technology Co., Ltd

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT03655678)
Sponsors:
Vertex Pharmaceuticals Inc.

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT04205435)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT04211480)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV (NCT05143307)
Sponsors:
Excision BioTherapeutics

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT03164135)
Sponsors:
Affiliated Hospital to Academy of Military Medical Sciences

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (2018-001320-19)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT03745287)
Sponsors:
Vertex Pharmaceuticals

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT04443907)
Sponsors:
Novartis Pharmaceuticals

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT04774536)
Sponsors:
Principal Investigator: Mark Walters, MD UCSF Benioff Children's Hospital Oakland

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT04819841)
Sponsors:
Graphite Bio Inc

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT04853576)
Sponsors:
Editas Medicine, Inc.

IND Enabling

Phase I

Phase II

Phase III

Transfusion Dependent Beta-Thalassaemia, TDT, (NCT04925206)
Sponsors:
EdiGene (GuangZhou) Inc.

IND Enabling

Phase I

Phase II

Phase III

Transfusion Dependent Beta-Thalassemia, TDT, (NCT04390971)
Sponsors:
Institute of Hematology and Blood Diseases Hospital

IND Enabling

Phase I

Phase II

Phase III

Cancer

Acute Lymphoblastic Leukemia, ALL, (NCT04037566)
Sponsors:
Xijing Hospital, The Fourth Military Medical University

IND Enabling

Phase I

Phase II

Phase III

Acute Myeloid Leukaemia, AML, (NCT04614636)
Sponsors:
Fate Therapeutics, Inc

IND Enabling

Phase I

Phase II

Phase III

Acute Myeloid Leukemia, AML, (NCT04849910)
Sponsors:
Vor Biopharma

IND Enabling

Phase I

Phase II

Phase III

Acute Myeloid Leukemia, AML, (NCT05066165)
Sponsors:
Intellia Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Advanced Hepatocellular Carcinoma, HCC, (NCT04417764)
Sponsors:
Central South University

IND Enabling

Phase I

Phase II

Phase III

B Cell Malignancies, B Cell Leukemia, B Cell Lymphoma, NHL, (NCT03398967)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

B Cell Malignancy, NHL, (NCT03166878)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

B- cell Acute Lymphoblastic Leukemia, ALL, (NCT04557436)
Sponsors:
Great Ormond Street Hospital for Children NHS Foundation Trust

IND Enabling

Phase I

Phase II

Phase III

B-cell Acute Lymphoblastic Leukemia, ALL, (NCT03232619)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

B-cell Acute Lymphoblastic Leukemia, ALL, (NCT03298828)
Sponsors:
Third Military Medical University

IND Enabling

Phase I

Phase II

Phase III

B-cell Acute Lymphoblastic Leukemia, ALL, (NCT04154709)
Sponsors:
Xuzhou Medical University

IND Enabling

Phase I

Phase II

Phase III

B-Cell Malignancies, NHL, (NCT04629729)
Sponsors:
Fate Therapeutics

IND Enabling

Phase I

Phase II

Phase III

B-cell Malignancy, NHL, (NCT04035434)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

B-cell Non-Hodgkin Lymphoma, NHL, (NCT04637763)
Sponsors:
Caribou Biosciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Billiary Tract Cancer, BTC, (NCT04976218)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

Bladder Cancer, Invasive, IBC, (NCT02863913)
Sponsors:
Peking University

IND Enabling

Phase I

Phase II

Phase III

Castrate-Resistant Prostate Cancer, CRPC, (NCT04768608)
Sponsors:
Zhejiang University

IND Enabling

Phase I

Phase II

Phase III

Esophageal Cancer, (NCT03081715)
Sponsors:
Hangzhou Cancer Hospital

IND Enabling

Phase I

Phase II

Phase III

Gastro-Intestinal Cancer, GI, (NCT04426669)
Sponsors:
Intima Bioscience, Inc.

IND Enabling

Phase I

Phase II

Phase III

Human papillomavirus (HPV) related cervical cancer, (NCT03057912)
Sponsors:
First Affiliated Hospital, Sun Yat-Sen University

IND Enabling

Phase I

Phase II

Phase III

Metastatic Non-small Cell Lung Cancer, NSCLC, (NCT02793856)
Sponsors:
Sichuan University

IND Enabling

Phase I

Phase II

Phase III

Multiple myeloma, MM (NCT05069935)
Sponsors:
Fate Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT03399448)
Sponsors:
University of Pennsylvania

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT03492268)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT03752541)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT04244656)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Multiple Solid Tumor Adult, (NCT03545815)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

Nasopharyngeal Carcinoma, (NCT03044743)
Sponsors:
Yang Yang, MD, PhD, MSCR, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

IND Enabling

Phase I

Phase II

Phase III

Non-small Cell Lung Cancer,NSCLC, (NCT03525782)
Sponsors:
First Affiliated Hospital of Guangdong Pharmaceutical University

IND Enabling

Phase I

Phase II

Phase III

Prostate Cancer, (NCT03525652)
Sponsors:
The First Affiliated Hospital of Guangdong Pharmaceutical University

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B cell malignancies, (NCT04227015)
Sponsors:
Zhejiang University

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Lymphoma, DLBCL, (NCT04026100)
Sponsors:
The First Affiliated Hospital of Nanjing Medical University

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Malignancies, (NCT03229876)
Sponsors:
Bioray Laboratories - Shanghai Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Malignancies, (NCT04933825)
Sponsors:
EdiGene Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-Cell Malignancies, Non-Hodgkin lymphoma, NHL, (2018-003916-38)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Malignancies, Non-Hodgkin lymphoma, NHL, (NCT04213469)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Relapsed refractory B- cell Acute Lymphoblastic Leukaemia, ALL, (2019-003462-40)
Sponsors:
Great Ormond Street Hospital for Children NHS Trust

IND Enabling

Phase I

Phase II

Phase III

Relapsed/Refractory Haematopoietic Malignancies (NCT04767308)
Sponsors:
Huazhong University of Science and Technology

IND Enabling

Phase I

Phase II

Phase III

Renal Cell Carcinoma, RCC, (NCT04438083)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Solid Tumor Adult, (NCT03747965)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

Solid tumors - Tumor infiltration lymphocytes, TILs (NCT04842812)
Sponsors:
Second Affiliated Hospital of Guangzhou Medical University

IND Enabling

Phase I

Phase II

Phase III

Solid tumors, (NCT05395052)
Sponsors:
Fate Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Solid Tumours, EDIT-201

Discontinued

Sponsors:
Editas Medicine

IND Enabling

Phase I

Phase II

Phase III

T-Cell Acute Lymphoblastic Leukaemia, T-ALL, (ChiCTR1900025311)
Sponsors:
Xinqiao Hospital of Chongqing, Second Affiliated Hospital of the Army Medical University, Hematology Department

IND Enabling

Phase I

Phase II

Phase III

T-Cell Chronic Lymphoblastic Leukaemia, CLL, (NCT04264078)
Sponsors:
Xinqiao Hospital of Chongqing

IND Enabling

Phase I

Phase II

Phase III

T-Cell Lymphoma, (NCT04502446)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Eye

Herpes Simplex Virus Refractory Keratitis, (NCT04560790)
Sponsors:
Shanghai BDgene Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Leber Congenital Amaurosis, LCA, (NCT03872479)
Sponsors:
Editas Medicine, Inc.

IND Enabling

Phase I

Phase II

Phase III

Metabolic Disorders

Type 1 Diabetes, T1D (NCT05210530)
Sponsors:
CRISPR Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Other Genetic Conditions

Transthyretin amyloidosis, ATTR, (NCT04601051)
Sponsors:
Intellia Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Search CRISPR Medicine